COMP <GO>
AXSM vs ABBV // FREE CASH FLOW YIELD
Axsome Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AXSM 3
— ABBV 9
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $144.43 (+0.68%) • MKT CAP: $7.51B
fcf-yield
-1.25%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | 29.00% | -50.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -1.25% | 3.47% | -4.72 | ABBV | /fcf-yield <GO> |
| Operating Margin | -26.10% | 24.60% | -50.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 6.90% | -35.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 8.60% | +56.90 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 5.33 | +0.01 | AXSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 24.3 | 72.8 | -48.46 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 113.1x | -78.10 | AXSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.51B | $513.86B | -$506.35B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | ABBV REV | AXSM GROSS % | ABBV GROSS % | AXSM FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $61.16B | 44.0% | 70.2% | -$93.9M | $17.82B |
| FY 2024 | $385.7M | $56.33B | 44.0% | 70.0% | -$128.7M | $17.83B |
| FY 2023 | $270.6M | $54.32B | 44.0% | 44.0% | -$157.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
ABBV // BETA 1.15